The World Anti-Doping Agency (WADA) monitors the use of GLP-1 receptor agonist drugs at the Winter Olympics. These drugs are under the scrutiny of an advisory group that makes recommendations on the WADA Prohibited List. Monitoring takes place in connection with the start of the Winter Olympics. GLP-1 agonists represent an unexpected group of drugs studied in the anti-doping context. WADA focuses on their potential misuse in sport.